<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409004</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-026-HV</org_study_id>
    <nct_id>NCT02409004</nct_id>
  </id_info>
  <brief_title>Effects of Rifampin on the Pharmacokinetics of Ataluren</brief_title>
  <official_title>A Phase I Study Assessing the Effects of Rifampin on the Pharmacokinetics of Ataluren in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single centre, Phase I, open-label, one cohort, one dose level,
      fixed-sequence, drug interaction study in healthy volunteers. The objective of this study is
      to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting
      conditions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>12 days</time_frame>
    <description>The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>12 days</time_frame>
    <description>The objective of this study is to determine the effects of rifampin on the pharmacokinetics of ataluren under fasting conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by adverse events, laboratory abnormalities, vital signs, and electrocardiogram parameters</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <arm_group_label>Ataluren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <arm_group_label>Ataluren</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Male

          -  Non-smoker

          -  ≥18 and ≤55 years of age

        Exclusion Criteria:

          -  Clinically significant laboratory, electrocardiogram, or vital sign abnormality at
             screening

          -  Positive urine drug screen at screening

          -  History of significant drug or alcohol abuse

          -  Recent use of medication other than topical products without significant systemic
             absorption

          -  Recent donation of plasma or blood or loss of blood
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Laskin, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphaël Vlavonou, PhD</last_name>
    <phone>418-527-4000</phone>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 31, 2015</lastchanged_date>
  <firstreceived_date>March 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
